Patterns Of Care For Hodgkin Lymphoma In Brazil: Real World Data From A Private Healthcare System
Hodgkin Lymphoma (HL) is a rare hematologic malignancy with an estimated 2,470 new cases projected for 2016 in Brazil.
Currently, patients diagnosed with early-stage disease receive combined-modality therapy consisting of two to four cycles of chemotherapy (usually adriamycin, bleomycin, vinblastine, and dacarbazine [ABVD]) followed by involved-field radiation therapy (1).
Patients with advanced HL are usually treated with six to eight cycles of chemotherapy (ABVD or escalated bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone [BEACOPP]), optionally followed by localized radiation therapy (1, 2).
More than 80% of all HL patients can be cured with standard first-line therapy (2, 3). Although the recommendation of clinical guidelines for the initial treatment of HL is consensual (1), treatment for relapsed or refractory patients after autologous stem cells transplant (ASCT) are subject to discussions (1, 4).
All Brazilian citizens have the right to use the public healthcare, where most of HL patient are treated. However, many patients use the private healthcare to avoid the lack of new technologies or long waiting periods for consultations in the public setting.
The objective of this study was to evaluate patient characteristics and treatment patterns for HL patients in a private setting in Brazil.
Cancer; lymphoma; hodgkin; Brazil.
How to cite
Zagadailov E, Andrade F, Barreto T, Gautam A, Clark O, Saad R, et al. Patterns Of Care For Hodgkin Lymphoma In Brazil: Real World Data From A Private Healthcare System. ISPOR USA; Boston: ISPOR; 2017.